Industry Focus | Life Sciences
Expertise Across the Value Chain
Outcome Capital recognizes that the life sciences marketplace evolves rapidly as revolutionary ideas that once held ‘future promise’ come to fruition.
From advances in personalized medicine and diagnostics to transformations in medical devices and therapeutics — not only are avenues of patient care changing but also the financial landscape and fluid interplay between life sciences sectors. The Outcome Capital Life Sciences team is dedicated to following the most recent scientific advancements as well as understanding their implications on market dynamics. The unmatched combination of scientific backgrounds and business acumen of Outcome professionals ensures they see the value of their clients’ businesses not only in today’s market but also the future potential enabling them to maximize value for their clients. Outcome Capital is a trusted partner to middle-market companies providing M&A, capital raise and advisory services in life sciences markets.
- Pharma/Biotech
- Diagnostics
- Medical Devices
- Life Science Tools and Research
- Contract Research and Manufacturing Organizations
Featured Transactions
Has been acquired by
$32 Million
Has Completed a Growth Equity Financing
Has Completed an Oversubscribed Growth Equity Round
Received an equity investment from
Has sold its business to
Has sold its business to
Has Acquired
$120 Million
Has Sold Its Business To
Has Sold Its Business To
Has Sold Its Business To
Has Issued 5,000,000 Shares of Series A Preferred Stock
Has Sold Its Business To
Completed Its Debt & Equity Financing & Distribution Agreement With
Has Sold Its Business To
Has Completed an Option Deal and Financing Led By
Has Sold Its Business To
$60,000,000 Series C Financing By a Group Led By
$15,000,000
$13,100,000 Series A1 Preferred Investment From a Group Led by
Has Sold Its Business To
$49,000,000 Histogenics Series A Preferred Investment From a Group Co-led by
$5,900,000 Spirus Medical Series A Preferred Investment From a Group Co-led by
Has Sold Its Business To
$5,300,000 Series A Preferred Investment From
$13,600,000 Series B Convertible Preferred Investment From a Group Led by
$9,000,000 Series B Preferred Investment From a Group Led by
Has Sold Its Business To
Outcome Capital is a proud member of the Massachusetts Biotechnology Council
News
Outcome Capital Announces Electronic Registry Systems (ERS) Acquisition by Health Catalyst
Boston – November 8, 2023 Outcome Capital, a specialized life science advisory and investment banking firm, today announced that Electronic Registry Systems, Inc. (ERS), a leading provider of cancer registry solutions and compliance and informatics services, has been acquired by Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a healthcare technology and data analytics company with […]
Read MoreResources
Outcome Capital Life Sciences Pulse, October 2023
Outcome Capital Life Science Market Pulse October 2023 Click to view our LifeSciences Pulse Newsletter
DownloadContact Us for More Information
Would you like to learn more about working with Outcome Capital or discuss your specific needs?
© Outcome Capital 2023. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Business Continuity Plan | Privacy Policy | Regulation Best Interest
